Almirall has entered an artificial intelligence (AI)-driven drug discovery collaboration with Absci for the development and commercialisation of new treatments for dermatological ailments.
The collaboration will unite Absci’s integrated drug creation platform with the dermatological capabilities of Almirall to develop AI-designed therapeutics against chronic and debilitating diseases.
Absci will leverage its de novo generative AI technology to design and market treatment candidates for two targets in dermatology.
The company is entitled to receive $650m in upfront fees, research and development (R&D) and approval-based milestone payments for the two programmes.
Almirall will also make royalty payments for these products to Absci.
Absci will expand its de novo AI drug creation portfolio into the dermatology field and expedite drug discovery for chronic inflammatory ailments.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Almirall R&D executive vice-president and chief sales officer Dr Karl Ziegelbauer stated: “Almirall chose Absci because their de novo platform brings truly novel innovation in solving the industry’s most challenging targets facing high unmet medical need.
“Our partnership underlines Almirall’s commitment to target innovative approaches to help patients suffering from severe skin diseases to achieve their dream of leading a healthy life.”
Absci’s integrated drug creation platform merges the data for training, AI for designing and the wet lab for verifying several AI-created designs per week.
It can advance such AI-developed antibodies to wet lab-verified candidates in a minimum of six weeks.
